Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Listing application of Ordinary Shares

28 Mar 2022 15:09

RNS Number : 2733G
ABCAM PLC
28 March 2022
 

For immediate release

28 March 2022

ABCAM PLC

 

("Abcam" or the "Company")

Block Listing application of Ordinary Shares

 

Cambridge, UK : Abcam plc (AIM: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that it has applied for a block admission for a further 4,350,000 ordinary shares of 0.2p each in the Company ("Ordinary Shares") to be admitted to trading on AIM on 29 March 2022. This will be used to facilitate the admission of shares to trading following the exercise of options granted under the following two share schemes:

· Abcam Growth Plan - 3,500,000 shares;

· Annual Bonus Plan - 850,000 shares.

 

The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

 

New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.

 

At the time of this announcement, Abcam plc has 228,908,563 Ordinary Shares in issue.

 

 

Date of Notification: 28 March 2022

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Marc Perkins, Company Secretary

 

Numis - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7260 1000

Garry Levin / Freddie Barnfield / Duncan Monteith

 

Morgan Stanley - Joint Corporate Broker

Tom Perry / Luka Kezic

 

 

+44 (0) 20 425 8000

 

FTI Consulting

Ben Atwell / Natalie Garland-Collins

 

 

+44 (0) 20 3727 1000

Notes to Editors

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

 

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

 

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

 

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

 

For more information, please visit  corporate.abcam.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSSEAFLAEESESD
Date   Source Headline
1st Oct 20204:41 pmRNSTotal Voting Rights
25th Sep 20201:33 pmRNSDirector/PDMR Shareholding
18th Sep 20202:19 pmRNSBlock listing Interim Review
18th Sep 20207:54 amRNSDirector/PDMR Shareholding
14th Sep 20207:00 amRNSFull Year Results 2020
11th Sep 202010:34 amRNSNotice of Results
1st Sep 20207:52 amRNSTotal Voting Rights
4th Aug 202012:57 pmRNSTotal Voting Rights
23rd Jul 20207:00 amRNSChange of Adviser
23rd Jul 20207:00 amRNSFull Year Trading Update
2nd Jul 202010:11 amRNSTotal Voting Rights
16th Jun 202012:00 pmRNSDirectorate Change
1st Jun 20209:29 amRNSTotal Voting Rights
11th May 202011:00 amRNSStatement re Update on 2019 AGM Resolution Vote
1st May 202012:24 pmRNSTotal Voting Rights
22nd Apr 202010:11 amRNSHolding(s) in Company
21st Apr 20207:26 amRNSDirector/PDMR Shareholding
20th Apr 202010:19 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 Update
14th Apr 202010:07 amRNSHolding(s) in Company
9th Apr 20205:33 pmRNSIssue of Shares
2nd Apr 20209:50 amRNSTotal Voting Rights
27th Mar 20203:37 pmRNSHolding(s) in Company
9th Mar 20207:00 amRNSInterim results for 6 months ended 31 Dec 2019
4th Mar 20207:00 amRNSAcquisition of Marker Gene Technologies
2nd Mar 20203:43 pmRNSTotal Voting Rights
2nd Mar 20208:00 amRNSBlock listing Interim Review
4th Feb 202010:49 amRNSTotal Voting Rights
30th Jan 20207:00 amRNSAbcam expands cell engineering capabilities
28th Jan 20202:31 pmRNSHolding(s) in Company
28th Jan 20202:29 pmRNSDirector/PDMR Shareholding
14th Jan 20207:00 amRNSAppointment of Chief Financial Officer
10th Jan 20207:00 amRNSHalf Year Trading Update
2nd Jan 20209:45 amRNSTotal Voting Rights
2nd Jan 20207:00 amRNSTransaction complete between Abcam and Expedeon
19th Dec 201910:05 amRNSHolding(s) in Company
4th Dec 20193:37 pmRNSHolding(s) in Company
2nd Dec 20193:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20199:30 amRNSTotal Voting Rights
21st Nov 201911:42 amRNSHolding(s) in Company
14th Nov 20197:00 amRNSAbcam Capital Markets Event
13th Nov 20194:45 pmRNSResult of AGM
11th Nov 20197:00 amRNSAbcam to acquire proteomics & immunology business
6th Nov 20199:06 amRNSDirector/PDMR Shareholding
1st Nov 201910:55 amRNSTotal Voting Rights
2nd Oct 20194:28 pmRNSHolding(s) in Company
2nd Oct 20191:49 pmRNSDirector/PDMR Shareholding
1st Oct 20192:22 pmRNSTotal Voting Rights
30th Sep 20191:35 pmRNSAnnual Financial Report
26th Sep 20192:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.